The Pharmacological Treatment of Obsessive-Compulsive Disorders

References

• Altschuler M. Massive doses of trifluoperazine in the treatment of compulsive rituals. American Journal of Psychiatry 1962; 119: 367
   PubMed Web of Science ®Google Scholar
• Ananth J., Pecknold J. C., Van Den Steen N., et al. Double-blind study of clomipramine and amitriptyline in obsessive neurosis. Progress in Neuropsy-chopharmacology 1981; 5: 257–262
   PubMedGoogle Scholar
• Ananth J., Solyom L., Bryntwick S., et al. Clomipramine therapy for obsessive-compulsive neurosis. American Journal of Psychiatry 1979; 136: 700–720
   PubMed Web of Science ®Google Scholar
• Ananth J., Solyom L., Solyom C., et al. Doxepin in the treatment of obsessive-compulsive neurosis. Psychosomatics 1975; 16: 185–187
   PubMed Web of Science ®Google Scholar
• Angst J., Theobald W. Tofranil. Verlag Stampfl, BerneSwitzerland 1980; 11–32
   Google Scholar
• Annesley P. T. Nardil response in a chronic obsessive-compulsive. British Journal of Psychiatry 1969; 115: 748
   PubMed Web of Science ®Google Scholar
• Ansseau M., Legros J. J., Mormont C., et al. Intranasal oxytocin in obsessive-compulsive disorder. Psychoneuroendocrinology 1987; 12: 231–236
   PubMed Web of Science ®Google Scholar
• Asberg M., Montgomery S. A., Ferris C., et al. A comprehensive psychopathological rating scale. Acta Psychiatrica Scandinavica Supplementum 1978; 271: 5–27
   PubMedGoogle Scholar
• Asberg M., Thoren P., Bertilsson L. Psychopharmacologic treatment of obsessive-compulsive disorder. Clomipramine treatment of obsessive disorder—biochemical and clinical aspects. Psychopharmacology Bulletin 1982; 1(8)13–21
   Google Scholar
• Baer L., Jenike M. A., Ricciardi J., et al. Personality disorders in patients with obsessive-compulsive disorders. Archives of General Psychiatry 1990; 296, in press
   Google Scholar
• Baer L., Minichiello W. E., Jenike M. A. Behavioral treatment of obsessive-compulsive disorder with concomitant bipolar affective disorder. American Journal of Psychiatry 1985; 14(2)358–360
   Google Scholar
• Bauer G., Nowak H. Doxepine: eine neues Antidepressivum Wirkungs-Verleich mil Amitriptyline. Arzneimittelforsch 1969; 1(9)1642–1646
   Google Scholar
• Baxter L. R. Two cases of obsessive-compulsive disorder with depression responsive to trazodone. Journal of Nervous and Mental Diseases 1985; 17(3)432–433
   Google Scholar
• Bertilsson L., Asberg M., Thoren P. Differential effect of clorimipramine and nortriptyline on cerebrospinal fluid amines and metabolites of serotonin and noradrenaline in depression. European Journal of Clinical Pharmacology 1974; 7: 365–368
   PubMed Web of Science ®Google Scholar
• Bertilsson L., Tuck J. R., Siwers B. Biochemical effects of zimelidine in man. European Journal of Clinical Pharmacology 1980; 1(8)483–487
   Google Scholar
• Bethume H. C. A new compound in the treatment of severe anxiety states: report on the use of diazepam. New England Journal of Medicine 1964; 6(3)153–156
   Google Scholar
• Black A. The natural history of obsessional neurosis. Obsessional States, H. R. Beech. Methuen and Co., London 1974
   Google Scholar
• Bodkin A., White K. Clonazepam in the treatment of obsessive-compulsive disorder. Journal of Clinical Psychiatry 1989, in press
   PubMedGoogle Scholar
• Breitner C. Drug therapy in obsessional states and other psychiatric problems. Diseases of the Nervous System 1960; 21((Suppl.))31–35
   PubMedGoogle Scholar
• Bremner J. D. Fluoxetine in depressed patients: a comparison with imipramine. Journal of Clinical Psychiatry 1984; 4(5)414–419
   Google Scholar
• Brickner R. M., Rosen A. A., Munro R. Physiological aspects of the obsessive state. Psychosomatic Medicine 1940; 2: 369–383
   Google Scholar
• Capstick N. Clinical experience in the treatment of obsessional states. Journal of International Medical Research 1977; 5((Suppl. 5))71
   PubMedGoogle Scholar
• Carey R. J., Baer L., Jenike M. A., et al. MMPI correlates of obsessive-compulsive disorder. Journal of Clinical Psychiatry 1986; 47: 371–372
   PubMed Web of Science ®Google Scholar
• Cohen D. J., Detlor J., Young J. G., et al. Clonidine ameliorates Gilles de la Tourette syndrome. Archives of General Psychiatry 1980; 37: 1350–1357
   PubMed Web of Science ®Google Scholar
• Cole J. O., Hartmann E., Brigham P. L-Tryptophan: clinical studies. McLean Hospital Journal 1980; 5: 37–71
   Google Scholar
• Coleman B. S., Block B. A. Fiuvoxamine maleate, a serotonergic antidepressant: a comparison with chlorimipramine. Progress in Neuropsychopharmacology and Biological Psychiatry 1982; 6: 475–478
   PubMed Web of Science ®Google Scholar
• Coombe P. D. Clomipramine and severe obsessive-compulsive neurosis. Australia & New Zealand Journal of Psychiatry 1982; 1(6)293–297
   Google Scholar
• Demontigny C., Grunberg F., Mayer A., et al. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. British Journal of Psychiatry 1981; 138: 252–256
   PubMed Web of Science ®Google Scholar
• DeVeaugh-Geiss J., Landau P., Katz R. Treatment of obsessive compulsive disorder with clomipramine. Psychology Annals 1989; 1(9)97–101
   Google Scholar
• DeVorvrie G. V. Anafranil (G34586) in obsessive neurosis. Acta Neural. Belg. 1968; 6(8)787–792
   Google Scholar
• Epstein A. W., Bailine S. H. Sleep and dream studies in obsessional neurosis with particular reference to epileptic states. Biological Psychiatry 1971; 3: 149–158
   PubMed Web of Science ®Google Scholar
• Feder R. Lithium augmentation of clomipramine. Journal of Clinical Psychiatry 1988; 49: 458
   PubMed Web of Science ®Google Scholar
• Fernandez C. E., Lopez-Ibor J. J. Monochlorimipramine in the treatment of psychiatric patients resistant to other therapies. Actas Luso. Esp. Neural. Psiquiatr. 1967; 2(6)119–147
   Google Scholar
• Foa E. B. Failure in treating obsessive-compulsives. Behaviour Research Therapy 1979; 1(7)169–176
   Google Scholar
• Foa E. B., Steketee G., Kozak M. J., et al. Effects of imipramine on depression and obsessive-compulsive symptoms. Psychiatry Research 1987a; 2(1)123–136
   Google Scholar
• Foa E. B., Steketee G., Kozak M. J., et al. Imipramine and placebo in the treatment of obsessive-compulsives: their effect on depression and on obsessional symptoms. Psychopharmacology Bulletin 1987b; 23: 8–11
   PubMedGoogle Scholar
• Fonagy P., Higgitt A. C. A note on statistical inference in meta-analysis. Behaviour Research Therapy 1983; 21(1)87–88
   PubMed Web of Science ®Google Scholar
• Fontaine R., Chouinard G. Antiobsessive effect of fluoxetine. American Journal of Psychiatry 1985; 142: 989
   PubMed Web of Science ®Google Scholar
• Fontaine R., Chouinard G. An open clinical trail of fluoxetine in the treatment of obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 1986; 6: 98–101
   PubMed Web of Science ®Google Scholar
• Fontaine R., Chouinard G. Fluoxetine in the long-term maintenance treatment of obsessive-compulsive disorder. Psychiatric Annals 1989; 1(9)88–91
   Google Scholar
• Forssman H., Walinder J. Lithium treatment of atypical indication. Acta Psychiatrica Scandinavica Supplementum 1969; 20(7)34–40
   Google Scholar
• Fontaine R., Chouinard G., Iny L. An open clinical trial of zimelidine in the treatment of obsessive-compulsive disorder. Current Therapy and Research 1985; 3(7)326–332
   Google Scholar
• Geisler A., Schou M. Lithium ved tvangsneuroser. Nord. Psychiatr. Tidsskr. 1970; 2(3)493–495
   Google Scholar
• Geissman P., Kammerer T. L'imipramine dans la neurose obsessionelle: etude de 39 cas. Encephale. 1964; 5(3)369–382
   Google Scholar
• Golden R. N., Morris J. E., Sack D. A. Combined lithium-tricyclic treatment of obsessive-compulsive disorder. Biological Psychiatry 1988; 2(3)181–185
   Google Scholar
• Goodman W. K., Price L. H., Rasmussen S. A., et al. Efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with placebo. Archives of General Psychiatry 1989a; 46: 36–44
   PubMed Web of Science ®Google Scholar
• Goodman W. K., Price L. P., Anderson G. M., et al (1989b) Drug response and obsessive compulsive disorder subtypes. APA Symposium, American Psychiatric Association Meetings, San Francisco, CA, 8 May, 1989
   Google Scholar
• Goodwin D. W., Guze S. B., Robins E. Follow-up studies in obsessional neurosis. Archives of General Psychiatry 1969; 20: 182–187
   PubMed Web of Science ®Google Scholar
• Grabowski J. R. Treatment of severe depression and obsessive depression with G3486. Folia Med. 1968; 5(7)265–270
   Google Scholar
• Greist J. H., Jefferson J. W., Rosenfeld R., et al. Clomipramine and obsessive-compulsive disorder: a placebo-controlled double-blind study in 32 patients. Journal of Clinical Psychiatry 1990; 51: 292–297
   PubMed Web of Science ®Google Scholar
• Gross M., Slater E., Roth M. Clinical Psychiatry. Tindall and Casel, Bailliere 1969
   Google Scholar
• Guelfi J. D., Dreyfus J. F., Pichot P. A double-blind controlled clinical trial comparing fluvoxamine with imipramine. British Journal of Clinical Pharmacology 1983; 1(5)411S–417S
   Google Scholar
• Guy W., Wilson W. H., Ban T. A., et al. A double-blind clinical trial of fluvoxamine and imipramine in patients with primary depression. Drug Development and Research 1984; 4: 143–153
   Web of Science ®Google Scholar
• Heym J., Koe B. K. Pharmacology of sertraline: a review. Journal of Clinical Psychiatry 1988; 49((8, Suppl))40–45
   PubMedGoogle Scholar
• Hill A., Mitchell W. Epileptic amnesia. Folia Psychiatr Neural Jpn 1953; 56: 718
   Google Scholar
• Hollander E., Liebowitz M. R. Augmentation of antiobsessional treatment with fenfluramine. American Journal of Psychiatry 1988; 14(5)1314–1315
   Google Scholar
• Hollander E., Fay M., Cohen B., et al. Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings. American Journal of Psychiatry 1988a; 145: 1015–1017
   PubMed Web of Science ®Google Scholar
• Hollander E., Fay M., Liebowitz M. R. Clonidine and clomipramine in obsessive-compulsive disorder. American Journal of Psychiatry 1988b; 14(5)388–389
   Google Scholar
• Hussain M. Z., Ahad A. Treatment of obsessive-compulsive neurosis. Canadian Medical Association Journal 1970; 10(3)648–650
   Google Scholar
• Insel T. R. New Findings in Obsessive-Compulsive Disorder. APA Press, Washington 1984
   Google Scholar
• Insel T. R., Pickar D. Naloxone administration in obsessive-compulsive disorder: report of two cases. American Journal of Psychiatry 1983; 140: 1219–1220
   PubMed Web of Science ®Google Scholar
• Insel T. R., Hamilton J., Guttmacher L., et al. D-Amphetamine in obsessive-compulsive disorder. Psychopharmacology 1983a; 80: 231–235
   PubMed Web of Science ®Google Scholar
• Insel T. R., Murphy D. L., Cohen R. M., et al. Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Archives of General Psychiatry 1988b; 40: 605–612
   Google Scholar
• Insel T. R., Roy B. F., Cohen R. M., et al. Possible development of the serotonin syndrome in man. American Journal of Psychiatry 1982; 139: 954–955
   PubMed Web of Science ®Google Scholar
• Itil T. M., Shrivastava R. K., Mukherjee S., et al. A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression. British Journal of Pharmacology 1983; 15: 433S–438S
   Web of Science ®Google Scholar
• Ja:n V. K., Swinson R. P., Thomas J. E. Phenelzine in obsessional neurosis. British Journal of Psychiatry 1970; 11(7)237–238
   Google Scholar
• Jenike M. A. Rapid response of severe obsessive-compulsive disorder to tranylcypromine. American Journal of Psychiatry 1981; 13(8)1249–1250
   Google Scholar
• Jenike M. A. Obsessive-compulsive disorder: a question of a neurologic lesion. Comprehensive Psychiatry 1984; 2(5)298–304
   Google Scholar
• Jenike M. A. Use of monoamine oxidase inhibitors in obsessive-compulsive disorder. British Journal of Psychiatry 1982; 140: 159
   Google Scholar
• Jenike M. A. Psychotherapy of the obsessional. Obsessive Compulsive Disorders: theory and management, M. A. Jenike, L Baer, W. E. Minichiello. PSG Publishing Co., Littleton, MA 1986a
   Google Scholar
• Jenike M. A. Somatic treatments. Obsessive Compulsive Disorders: theory and management, M. A. Jenike, L Baer, W. E. Minichiello. PSG Publishing Co., Littleton, MA 1986b
   Google Scholar
• Jenike M. A. Obsessive-compulsive and related disorders: a hidden epidemic. New England Journal of Medicine 1989; 32(1)539–541
   Google Scholar
• Jenike M. A. Approaches to the patient with treatment-refractory obsessive-compulsive disorder. Journal of Clinical Psychiatry 1990; 51((2, Suppl.))15–21
   PubMedGoogle Scholar
• Jenike M. A., Baer L. Buspirone in obsessive-compulsive disorder: an open trial. American Journal of Psychiatry 1988; 14(5)1285–1286
   Google Scholar
• Jenike M. A., Brotman A. W. The EEC in obsessive-compulsive disorder. Journal of Clinical Psychiatry 1984; 4(5)122–124
   Google Scholar
• Jenike M. A., Surman O. S., Cassem N. H., et al. Monoamine oxidase inhibitors in obsessive-compulsive disorder. Journal of Clinical Psychiatry 1983; 44: 131–132
   PubMed Web of Science ®Google Scholar
• Jenike M. A., Baer L., Minichiello W. E., et al. Concomitant obsessive-compulsive disorder and schizotypal personality disorder: a poor prognostic indicator. Archives of General Psychiatry 1986a; 43: 296
   PubMed Web of Science ®Google Scholar
• Jenike M. A., Baer L., Minichiello W. E., et al. Concomitant obsessive-compulsive disorder and schizotypal personality disorder. American Journal of Psychiatry 1986b; 143: 530–533
   PubMed Web of Science ®Google Scholar
• Jenike M. A., Buttolph L., Baer L., et al. Fluoxetine in obsessive-compulsive disorder: a positive open trial. American Journal of Psychiatry 1989a; 146: 909–911
   PubMed Web of Science ®Google Scholar
• Jenike M. A., Baer L., Summergrad P., et al. Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27patients. American Journal of Psychiatry 1989b; 146: 1328–1330
   PubMed Web of Science ®Google Scholar
• Jenike M. A., Baer L., Buttolph L. Buspirone augmentation of fluoxetine in patients with obsessive–compulsive disorder (submitted). 1990a
   Google Scholar
• Jenike M. A., Baer L., Greist J. H. Clomipramine vs. fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy. Journal of Clinical Psychopharmacology 1990b; 10: 122–124
   PubMed Web of Science ®Google Scholar
• Jenike M. A., Baer L., Minichiello W. E. Obsessive-Compulsive Disorders: theory and management2nd edn. Mosby Year Book, Chicago, IL 1990c
   Google Scholar
• Jenike M. A., Hyman S. E., Baer L., et al. Fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with Placebo in 40 patients. American Journal of Psychiatry 1990c, in press
   Web of Science ®Google Scholar
• Jiminez F. A clinical study of Anafranil in depressive, obsessional and schizophrenic patients. Folia Neuropsiquat. Sur. Este. Esp. 1990d; 3: 189
   Google Scholar
• Joel S. W. Twenty month study of iproniazid therapy. Diseases of the Nervous System 1959; 20: 1–4
   Google Scholar
• Joffe R. T., Swinson R. P. Carbamazepine in obsessive-compulsive disorder. Biological Psychiatry 1987; 2(2)1169–1171
   Google Scholar
• Kahn R. S., Westenberg H. G. M., Jolles J. Zimelidine treatment of obsessive-compulsive disorder. Acta Psychiatrica Scandinavica 1984; 6(9)529–261
   Google Scholar
• Kendell R. E., Discipio W. J. Obsessional symptoms and obsessional personality traits in patients with depressive illness. Psychology in Medicine 1968; 1: 65–72
   Google Scholar
• Khanna S. Carbamazepine in obsessive-compulsive disorder. Clinical Neuropharmacology 1988; 1(1)478–481
   Google Scholar
• Kim S. W. Trazodone in the treatment of obsessive-compulsive disorder: a case report. Journal of Clinical Psychopharmacology 1970; 7: 278–279
   Google Scholar
• Knesevich J. W. Successful treatment of obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 1987; 7: 278–279
   PubMed Web of Science ®Google Scholar
• Koe B. K., Weisman A., Welch W. M., et al. Sertraline, a new uptake inhibitor with selectivity for serotonin. Journal of Pharmacological and Experimental Therapy 1982; 226: 686–700
   Web of Science ®Google Scholar
• Lader M., Wing L. Physiological measures in agitated and retarded depressed patients. Journal of Psychiatric Research 1983; 7: 89–100
   Google Scholar
• Lopez-Ibor J. J. Intravenous infusions of mono-chlorimipramine. Technique and results Proceedings of the Sixth International Congress of the CINP, TaragonaSpain, April, 1968. Amsterdam, 519–521, Exerpta Medica Foundation Int Congress Series No. 180
   Google Scholar
• Lydiard R. B. Obsessive-compulsive disorder successfully treated with trazodone. Psychosomatics 1986; 2(7)858–859
   Google Scholar
• Markovttz P. J., Stagno S. J., Calabrese J. R. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. Abstract 379, Biological Psychiatry Annual Meeting, San Francisco, May, 1989
   Google Scholar
• Marks I. M. Review of behavioral psychotherapy, I: obsessive-compulsive disorders. American Journal of Psychiatry 1969; 138: 584–592
   Google Scholar
• Marks I. M., Stern R. S., Mawson D., et al. Clomipramine and exposure for obsessive-compulsive rituals. British Journal of Psychiatry 1981; 136: 1–25
   Web of Science ®Google Scholar
• Marshall W. K., Micev V. Clomipramine in the treatment of obsessional illness and phobic anxiety states. Journal of International Medical Research 1980; 1: 403–412
   Google Scholar
• McDougle C. J., Goodman W. K., Price L. H., et al. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder: an open case series (submitted). 1973
   Google Scholar
• McElroy S. L., Pope H. G. Use of anticonvulsants in Psychiatry: recent advances. Oxford Health Care, Cliffon, NJ 1989
   Google Scholar
• McElroy S. L., Keck P. E., Pope H. G. Sodium valproate: its use in primary psychiatric disorders. Journal of Clinical Psychopharmacology 1988; 7: 16–24
   Web of Science ®Google Scholar
• Minichiello W. E., Baer L., Jenike M. A. Schizotypal personality disorder: a poor prognostic indicator for behavior therapy in the treatment of obsessive-compulsive disorder. Journal of Anxiety Diseases 1987; 1: 273–276
   Google Scholar
• Monteiro W. O., Noshirvani H. F., Marks I. M., et al. Anorgasmia from clomipramine in obsessive-compulsive disorder: a controlled trial. British Journal of Psychiatry 1987; 151: 107–112
   PubMed Web of Science ®Google Scholar
• Montgomery S. A. Clomipramine in obsessional neurosis: a placebo controlled trial. Pharmacological Medicine 1987; 1: 189–192
   Google Scholar
• O'Regan B. Treatment of obsessive-compulsive disorder, letter. Canadian Medical Association Journal 1980; 103: 648–650
   Google Scholar
• O'Oegan B. Treatment of obsessive-compulsive neurosis with haloperidol. Canadian Medical Association Journal 1970b; 10(3)167–168
   Google Scholar
• Orvin G. H. Treatment of the phobic obsessive-compulsive patient with oxazepam, an improved benzodiazepine compound. Pschosomatics 1970a; 8: 278–280
   Google Scholar
• Pacella B. L., Polantin P., Nagler S. H. Clinical and EEG studies in obsessive-compulsive states. American Journal of Psychiatry 1944; 100: 830–838
   Google Scholar
• Pato M. T., Pigott T. A., Hill J. L., et al (1967) Clomipramine versus buspirone in OCD: a controlled trial. New Research Symposium. American Psychiatric Association Meeting, San Francisco, CA, 8 May, 1989
   Google Scholar
• Pato M. T., Zohar-Kadouch R., Zohar J., et al. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. American Journal of Psychiatry 1989; 145: 1521–1525
   Web of Science ®Google Scholar
• Perse T. L., Greist J. H., Jefferson J. W., et al. Fluvoxamine treatment of obsessive-compulsive disorder. American Journal of Psychiatry 1988; 144: 1543–1548
   Web of Science ®Google Scholar
• Pickar D., Cohen M. R., Naber D., et al. Clinical studies of the endogenous opioid system. Biological Psychiatry 1987; 17: 1243–1276
   Google Scholar
• Prasad A. Efficacy of trazodone as an antiobsessional agent. Pharmacology, Biochemistry and Behaviour 1985; 2(2)347–348
   Google Scholar
• Prasad A. J. Obsessivecompulsive disorder and trazodone. American Journal of Psychiatry 1984; 14(1)612–613
   Google Scholar
• Price L. H., Goodman W. K., Charney D. S., et al. Treatment of severe obsessive-compulsive disorder with fluvoxamine. American Journal of Psychiatry 1982; 144: 1059–1061
   Google Scholar
• Rack P. H. Clinical experience in the treatment of obsessed states. Journal of International Medical Research 1987; 5((Suppl. 5))81–96
   Google Scholar
• Rapoport J., Elkins R., Mikkelsen A., et al. Clinical controlled trial of clorimipramine in adolescents with obsessive-compulsive disorder. Psychopharmacol Bulletin 1977; 3: 61–63
   Google Scholar
• Rasmussen S. A. Lithium and tryptophan augmentation in clomipramine-resistant obsessive-compulsive disorder. American Journal of Psychiatry 1984; 14(1)1283–1285
   Google Scholar
• Rasmussen S. A., Tsuang M. T. Epidemiology and clinical features of obsessive-compulsive disorder. Obsessive Compulsive Disorders: theory and management, M. A. Jenike, L Baer, W. E. Minichiello. PSG Publishing, Inc., Littleton, MA 1980
   Google Scholar
• Rasmussen S. A., Goodman W. K., Woods S. W., et al. (1987) Effects of yohimbine in obsessive-compulsive disorder. Psychopharmacology 1986; 93: 308–313
   Web of Science ®Google Scholar
• Rihmer Z., Szantok Arato M., et al. Response of phobic disorders with obsessive symptoms to MAO inhibitors. American Journal of Psychiatry 1982; 139: 1374
   PubMed Web of Science ®Google Scholar
• Rivers-Bugkeley N., Hollander M. H. Successful treatment of obsessive-compulsive disorder with loxapine. American Journal of Psychiatry 1982; 13(9)1345–1346
   Google Scholar
• Salzman L. Obsessional Personality. Science House, New York 1969
   Google Scholar
• Sandyk R. Naloxone abolishes obsessive-compulsive behavior in Tourette's syndrome. International Journal of Neuroscience 1987; 3(5)93–94
   Google Scholar
• Segal D. S., Brown R. G., Arnsten A., . Characteristics of beta endorphin-induced behavioral activation and immobilization. Endorphins in Mental Health Research, E Usdin, W. E. Bunney, Jr, N. S. Kline, et al. Oxford University Press, New York 1979
   Google Scholar
• Sewell R. D. E., Lee R. L. Opiate receptors, endorphins, and drug therapy. Postgraduate Medical Journal 1980; 56((Suppl. 1))2530
   Google Scholar
• Snyder S. Amitriptyline therapy of obsessive-compulsive neurosis. Journal of Clinical Psychiatry 1980; 4(1)286–289
   Google Scholar
• Steiner W., Fontaine R. Toxic reaction following the combined administration of fluozetine and L-tryptophan: five case reports. Biological Psychiatry 1986; 2(1)1067–1071
   Google Scholar
• Stern T. A., Jenike M. A. Treatment of obsessive-compulsive disorder with lithium carbonate. Psychosomatics 1983; 2(4)671–673
   Google Scholar
• Stroebel C. F., Szarek B. L., Glueck B. C. Use of clomipramine in treatment of obsessive-compulsive symptomatology. Journal of Clinical Psychopharmacology 1984; 4: 98–100
   PubMed Web of Science ®Google Scholar
• Swinson R. P. Response to tranylcypromine and thought stopping in obsessional disorder. British Journal of Psychiatry 1984; 14(4)425–427
   Google Scholar
• Tesar G. E., Jenike M. A. Alprazolam as treatment for a case of obsessive-compulsive disorder. American Journal of Psychiatry 1984; 14(1)689–690
   Google Scholar
• Thoren P., Åsberg M., Cronholm B., et al. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Psychiatry 1980a; 37: 1281–1285
   Google Scholar
• Thoren P., Åsberg M., Cronholm B., et al. Clomipramine treatment of obsessive-compulsive disorder. II. Archives of General Psychiatry 1980b; 37: 1286–1294
   Web of Science ®Google Scholar
• Tollefson G. Alprazolam in the treatment of obsessive symptoms. Journal of Clinical Psychopharmacology 1985; 5: 39–42
   PubMed Web of Science ®Google Scholar
• Traskman L., Asberg M., Bertilsson L., et al. Plasma levels of clorimipramine and its demethyl-metabolite during treatment of depression. Differential biochemical and clinical effects of the two compounds. Clinical Pharmacological Therapy 1979; 26: 600–610
   PubMedGoogle Scholar
• Turner S. M., Hersen M., Bellack A. S., et al. Behavioral and pharmacological treatment of obsessive-compulsive disorders. Journal of Nervous and Mental Diseases 1980; 168: 651–657
   PubMed Web of Science ®Google Scholar
• Turner S. M., Jacob R. G., Beidel D. C., et al. Fluoxetine treatment of obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 1985; 5: 207–212
   PubMed Web of Science ®Google Scholar
• Vangaard T. A typical endogenous depression. Acta Psychiatrica Scandinavica Supplementum 1976; 26(7)5–56
   Google Scholar
• Van Putten T., Sander D. G. Lithium in treatment failures. Journal of Nervous and Mental Diseases 1975; 16(1)255–264
   Google Scholar
• Venkoba Rao A. A controlled trial with valium in obsessive-compulsive states. Journal of the Indian Medical Association 1964; 4(2)564–567
   Google Scholar
• Walinder J., Skott A., Carlsson A., et al. Potentiation of the antidepressant action of clomipramine by tryptophan. Archives of General Psychiatry 1976; 33: 1384–1389
   PubMed Web of Science ®Google Scholar
• Watts V. S., Neill J. R. Buspirone in obsessive-compulsive disorder. American Journal of Psychiatry 1988; 145: 1606
   PubMed Web of Science ®Google Scholar
• Waxman D. A clinical trial of Clomipramine and diazepam in the treatment of phobic and obsessional illness. Journal of International Medical Research 1977; 5((Suppl. 5))99–110
   PubMedGoogle Scholar
• White K., Cole J. Pharmacotherapy. Handbook of Comparative Treatments, A. S. Bellack, M. Hersen. Wiley, New York 1990; 266–284
   Google Scholar
• White K., Keck P. E., Lipinski J. Serotonin-uptake inhibitors in obsessive-compulsive disorder: a case report. Psychiatry 1986; 2(7)211–214
   Google Scholar
• Wyndowe J., Solyom L., Ananth J. Anafranil in obsessive-compulsive nurosis. Current Therapy and Research 1975; 1(8)611–617
   Google Scholar
• Yaryura-Tobias J. A. Tryptophan may be adjuvant to obsessive-compulsive therapy. Clinical Psychiatric News, September 1981 1981; 16
   Google Scholar
• Yaryura-Tobias J. A., Neziroglu M. S. The action of clorimipramine in obsessive-compulsive neurosis: a pilot study. Current Therapy and Research 1975; 17: 1
   PubMed Web of Science ®Google Scholar
• Yaryura-Tobias J. A., Bhagavan H. N. L-Tryptophan in obsessive-compulsive disorders. American Journal of Psychiatry 1977; 13(4)1298–1299
   Google Scholar
• Yaryura-Tobias J. A., Neziroglu M. S., Bergman L. Clomipramine for obsessive-compulsive neurosis: an organic approach. Current Therapy and Research 1976; 20: 541–548
   Web of Science ®Google Scholar
• Yaryura-Tobias J. A., Neziroglu M. S., Bhagavan H. Obsessive-compulsive disorders: a serotonergic hypothesis. Neuropsychopharmacology: Proceedings of the 11th Congress of the CINP, B Saletu, P Berner, L. Hollister. Pergamon Press, Oxford 1979; 117–125
   Google Scholar